Dr Lal PathLabs

May 14, 2018

The National Stock Exchange of India Limited
Exchange Plaza
Bandra Kurla Complex, Bandra (E)
Mumbai - 400051

The Bombay Stock Exchange Limited
15th Floor, Phiroze Jeejeeboy Towers
Dalal Street,
Mumbai – 400001

Subject: Press Release for Audited Financial Results for the Quarter and Financial Year ended March 31, 2018

Dear Sir/Madam,

Please find enclosed herewith the Press Release for the Audited Financial Results (Standalone and Consolidated) for the Quarter and Financial Year ended March 31, 2018.

You are requested to take note of the above.

Thanking You,

Yours Faithfully,

For **Dr. Lal PathLabs Limited**

Dr Lal PathLabs Limited

Rajat Kalra
Company Secretary & Legal Head

Encl: As above

For Immediate Release **May 14, 2018**

Dr. Lal PathLabs Limited records revenue growth of 21.4% in Q4FY2017-18.
Full year revenue grows 15.8% to Rs 10569 mn

New Delhi, India, May 14, 2018 – Dr. Lal PathLabs Limited (referred to as the "Company"; NSE: LALPATHLAB, BSE: 539524), a leading diagnostic and related healthcare service provider announces their financial results for the quarter and full year ended March 31, 2018

Consolidated Performance Highlights: Q4FY2017-18 vs. Q4FY2016-17
Revenue growth: 21.4% Normalised EBITDA at Rs 688 mn, PBT at Rs 620 mn
Normalised EBITDA margins healthy at 25.8% vs 24.8% last year and
PBT margin at 23.2%Final Dividend Rs 3 per share recommended

- Kolkata Reference lab commences testing operations
- Operating Revenue increased by 21.4% in Q4 to Rs. 2668 million vs Rs 2199 million in the previous year same quarter. Underlying volume growth is 20.8% during the quarter. For the full year FY18 revenue grew 15.8% to Rs 10569 million with volume growing 15%
- Normalised EBITDA in Q4FY18 grew 26.3% to Rs.688 million from Rs 545 million in the same quarter last year, after adjusting for RSU, other stock based compensation costs and CSR expense. Full year normalised EBITDA grew 12.2% to Rs 2783 mn
- EBITDA Margin was improved to 25.8% for Q4 FY18 vs 24.8% in Q4 FY17 and for the full year the EBITDA margin was 26.3%
- PBT was Rs 620 mn in Q4 vs Rs 488 mn in Q4 last year while full year PBT increased to Rs 2613 mn from Rs 2368 mn
- Profit after Tax in Q4FY18 at Rs. 402 million compares with Rs 316 million in Q4 last year. Full year PAT at Rs 1718 mn grew 10.4%
- Final dividend recommended Rs 3 per equity share of Rs 10 each. This is in addition to the interim dividend of Rs 1.50 already paid out

Financial Overview (Consolidated) in Rs mn

Particulars (Rs Mn)	FY'18	FY'17	*Gr %*	MQ FY'18	MQ FY'17	*Gr %*
Total Revenue	**10,569**	**9,124**	***15.8%***	**2,668**	**2,199**	***21.4%***
Total Expenditure	7,929	6,749		2,028	1,700	
EBITDA	**2,640**	**2,375**	***11.2%***	**640**	**499**	***28.3%***
Adj for RSU, stock based comp. & CSR cost	143	105		48	46	
Normalised operating EBITDA	**2,783**	**2,480**	***12.2%***	**688**	**545**	***26.3%***
Normalised Margins	*26.3%*	*27.2%*		*25.8%*	*24.8%*	
Other income incl interest	312	275	*13.4%*	89	67	*32.4%*
PBT	**2,613**	**2,368**	***10.3%***	**620**	**488**	***27.0%***
Margins	*24.7%*	*26.0%*		*23.2%*	*22.2%*	
PAT	**1,718**	**1,556**	***10.4%***	**402**	**316**	***27.2%***
Margins	*16.3%*	*17.1%*		*15.1%*	*14.4%*	
EPS (Basic)	**20.85**	**19.02**	***9.6%***	**4.88**	**3.85**	***26.8%***
EPS (Diluted)	**20.82**	**18.95**	***9.9%***	**4.87**	**3.84**	***26.8%***

Figures have been recast as per Ind AS requirements

About Dr. Lal PathLabs Limited

Dr. Lal PathLabs is a provider of diagnostic and related healthcare tests and services in India. Through its integrated, nationwide network, the company offer patients and healthcare providers a broad range of diagnostic and related healthcare tests and services for use in core testing, patient diagnosis and the prevention, monitoring and treatment of disease and other health conditions.

Dr. Lal PathLabs has built a national, "hub and spoke" network that includes its National Reference Laboratory in New Delhi, Regional Reference Lab in Kolkata and 191 other clinical laboratories, 2153 patient service centers and 5,624 pickup points as of March 31, 2018. Their customers include individual patients, hospitals and other healthcare providers and corporate customers.

Contact Details

Dilip Bidani
Dr. Lal PathLabs Limited
+91 124 3016500
cfo@lalpathlabs.com

Aparna Agarwal
Adfactors PR
+91 9811177405
aparna.agarwal@adfactorspr.com

For further information on Dr. Lal PathLabs see www.lalpathlabs.com

Safe Harbour

This release contains statements that contain "forward looking statements" including, but without limitation, statements relating to the implementation of strategic initiatives, and other statements relating to Dr. Lal PathLabs future business developments and economic performance. While these forward looking statements indicate our assessment and future expectations concerning the development of our business, a number of risks, uncertainties and other unknown factors could cause actual developments and results to differ materially from our expectations. These factors include, but are not limited to, general market, macro-economic, governmental and regulatory trends, movements in currency exchange and interest rates, competitive pressures, technological developments, changes in the financial conditions of third parties dealing with us, legislative developments, and other key factors that could affect our business and financial performance. Dr. Lal PathLabs undertakes no obligation to publicly revise any forward looking statements to reflect future / likely events or circumstances.